Treatment of NIDDM in youth.
This study presents the characteristics of 20 children (17 female) with NIDDM who required oral hypoglycemic agent (OHA) therapy. A family history of NIDDM was present in 55%. None had islet cell antibodies (ICA) or glutamic acid decarboxylase (GAD) antibodies. Tolbutamide was the drug of choice; glibenclamide was introduced if glycemic control was not obtained after 2 to 3 months of tolbutamide therapy. Seven of the patients eventually required insulin therapy.
Owada
M
M
Department of Pediatrics, Nihon University Hospital, Tokyo, Japan.
Nitadori
Y
Y
Kitagawa
T
T
D000293:Adolescent; D002648:Child; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D012572:School Health Services; D014044:Tolbutamide / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D014044:Tolbutamide; D005905:Glyburide